Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-27T12:47:52.583Z Has data issue: false hasContentIssue false
  • English
  • Français

Calmodulin-Dependent Cyclic Nucleotide Phosphodiesterase in Human Cerebral Cortex and Glioblastoma Multiforme

Published online by Cambridge University Press:  18 September 2015

Sumeer Lal ,
Rajala V.S. Raju ,
Robert J.B. Macaulay  and
Rajendra K. Sharma
Sumeer Lal
Affiliation:
Division of Neurosurgery, Department of Surgery, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon
Rajala V.S. Raju
Affiliation:
Department of Pathology and Saskatoon Cancer Centre, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon
Robert J.B. Macaulay
Affiliation:
Department of Pathology and Saskatoon Cancer Centre, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon
Rajendra K. Sharma*
Affiliation:
Department of Pathology and Saskatoon Cancer Centre, College of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon
*
Department of Pathology, University of Saskatchewan, B419 Health Science Building, 107 Wiggins Road, Saskatoon, Saskatchewan, Canada S7N 5E5
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) has been extensively studied and characterized in normal mammalian tissues; however very little is known about this enzyme in human brain tumors. It has been established that high levels of this enzyme exist in non-central nervous system tumors, PDE inhibitors or cAMP analogues have been used to treat them. This study has examined the levels of CaMPDE in glioblastoma multiforme from six patients and has compared these to the levels of CaMPDE in four patients with normal cerebral tissue. In addition, an enzyme immune assay method (EIA) was developed in this study for the detection of CaMPDE in human cerebral tissue. This method is proposed to be used as an adjunct to the spectrophotometric method presently utilized. This would be beneficial in cases where small tissue samples, for example in stereotactic biopsy, are available. Methods: The CaMPDE activity and corresponding levels of expression in cerebral tissue from temporal lobectomies and both surgical extraction or stereotactic biopsy in patients with primary tumors were determined by spectophotometric and EIA, respectively. The EIA was developed from the production of a polyclonal antibody against bovine brain 60 kDa CaMPDE isozyme. Cross reactivity of the antibody with human was confirmed using transblot and immunohistochemistry. Results: Utilising the EIA, there was found to be significant reduction in both catalytic activity (p < 0.001) and in quantitative protein expression (p < 0.001) in glioblastoma multiforme from patients when compared to normal cerebral cortex. Immunoblotting experiments and immunohistochemistry demonstrated that CaMPDE in glioblastoma multiforme failed to react with a polyclonal antibody raised against bovine brain 60 kDa CaMPDE isozyme, whereas the enzyme from normal tissue reacted with antibody. Conclusions: Contrary to other studies on non-CNS tumors, the catalytic activity and the protein expression of CaMPDE is reduced in glioblastoma multiforme. The EIA method is a more sensitive in detecting CaMPDE than in the spectrophotometric method, especially when a small amount of tissue is available. Immunohistochemistry and the EIA may be useful in the future to use as markers for other types of brain tumors and not for glioblastoma multiforme as demonstrated.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 23 , Issue 4 , November 1996 , pp. 245 - 250
Copyright
Copyright © Canadian Neurological Sciences Federation 1996

References

1.Hickie, RA, Walker, CM, Croll, GA.Decreased cyclic adenosine 3’:5’-monophosphate levels in Morris hepatoma 5123 t.c.(h). Biochem Biophys Res Commun 1974; 59: 167–173.CrossRefGoogle ScholarPubMed
2.Hickie, RA, Jan, SH, Datta, A.Comparative adenylate cyclase activities in homogenate and plasma membrane fractions in Morris hepatoma 5123 t.c.(h). Cancer Res 1975; 35: 596–600.Google Scholar
3.Hickie, RA, Walker, CM, Datta, A.Increased activity of low Km cyclic adenosine 3’:5’-monophosphate phosphodiesterases in Morris hepatoma 5123 t.c.(h). Cancer Res 1975; 35: 601–605.Google Scholar
4.Hickie, RA.Regulation of cyclic AMP and cyclic GMP, In: Morris, HP, Criss, WE, eds. Morris Hepatomas: Mechanisms of Regulation. New York: Plenum Publishing Corp., 1978: 451–488.Google Scholar
5.Halfman, DM, Kuo, JF.A homogeneous cyclic CMP phosphodiesterase hydrolyzes both pyrimidine and purine cyclic 2’:3’- and 3’:5’-nucleotides. J Biol Chem 1982; 257: 1044–1047.CrossRefGoogle Scholar
6.Whitfield, JF.Calcium signals and cancer. Clin Rev Oncogenesis 1992; 3: 55–90.Google ScholarPubMed
7.Yan, C, Bentley, JK, Sonnenburg, W, et al. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci 1994; 14: 973–984.CrossRefGoogle ScholarPubMed
8.Epstein, PM, Hachisu, R.Cyclic neucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts. Adv Cyclic Nuc Prot Phosph 1984; 16: 303–324.Google Scholar
9.Onali, P, Strada, SJ, Chang, L, et al. Purification and characterization of high-affinity cyclic adenosine 5’-monophophate phosphodiesterases from human actue myelogenous leukemic cells. Cancer Res 1985; 45: 1384–1391.Google Scholar
10.Aleksijec, A, Lungnier, C, Giron, C, et al. Cyclic AMP and cyclic GMP phosphodiesterase activities in Hodgkin’s disease lymphocytes. Int J Immunopharmacol 1987; 9: 525–531.CrossRefGoogle Scholar
11.Wei, J-W, Hickie, RA.Decrease activities of cyclic cytidine 3’:5’ monophosphate phosphodiesterase in Morris hepatomas having varying growth rates. Int J Biochem 1983; 15: 789–795.CrossRefGoogle Scholar
12.Turnbull, JL, Hickie, RA.The isolation and characterization of cyclic nucleotide phosphodiesterase from Morris hepatoma 5123 t.c.(h) and rat liver. Int J Biochem 1984; 16: 19–29.CrossRefGoogle Scholar
13.Kumar, S, Becker, G, Prasad, KN.Cyclic adenosine 3’:5’-monophosphate phosphodiesterase activity in malignant and cyclic adenosine 3’:5’-monophosphate-induced “differentiated” neuroblastoma cells. Cancer Res 1975; 35: 82–87.Google Scholar
14.Singer, AL, Sherwin, RP, Dunn, AS, et al. Cyclic nucleotide phosphodiesterase in neoplastic and non-neoplastic mammary tissues. Cancer Res 1976; 36: 60–66.Google Scholar
15.Kakiuchi, S, Yamazaki, R.Calcium-dependent phosphodiesterase activity and its activating factor (PAF) from brain studies on cyclic 3’: 5’-nucleotide phosphodiesterase. Biochem Biophys Res Commun 1970; 41: 1104–1110.CrossRefGoogle Scholar
16.Kakiuchi, S, Yamazaki, R, Teshima, Y, et al. Regulation of nucleotide cyclic 3’:5’ monophosphate phosphodiesterase activity from rat brain by a modulator and Ca2+. Proc Natl Acad Sci USA 1973; 70: 3526–3530.CrossRefGoogle Scholar
17.Cheung, WY.Cyclic 3’:5’-nucleotide phosphodiesterase. Determination of activator. Biochem Biophys Res Commun 1970; 38: 533–538.CrossRefGoogle Scholar
18.Teo, TS, Wang, JH.Mechanisms of activation of cyclic adenosine 3’:5’ monophosphate phosphodiesterase from bovine heart by calciumions. J Biol Chem 1973; 248: 5950–5955.CrossRefGoogle Scholar
19.Sharma, RK.Calmodulin-stimulated cyclic nucleotide phosphodiesterase isozymes. Mol Aspects Cell Reg 1988; 5: 265–295.Google Scholar
20.Wang, JH, Sharma, RK, Mooibroek, MJ.Calmodulin stimulated cyclic nucleotide phosphodiesterase. Mol Pharm Cell Reg 1990; 2: 19–59.Google Scholar
21.Sharma, RK, Hickie, RA.Ca2+-calmodulin dependent cyclic nucleotide phosphodiesterase (PDEI)In: Dent, G, Klaus, R and Schudt, C, eds. The Handbook of Immunopharmacology-Phosphodiesterase Inhibitors. LondonAcademic Press, 1996: (in press).Google ScholarPubMed
22.Wells, JM, Hardman, JG.Cyclic nucleotide phosphodiesterases. Adv Cyclic Nucleotide Res 1977; 8: 119–143.Google ScholarPubMed
23.Hansen, RS, Beavo, JA.Purification of two calcium calmodulindependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography. Proc Natl Acad Sci USA 1982; 79: 2788–2792.CrossRefGoogle ScholarPubMed
24.Sharma, RK.Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry 1991; 30: 5964–5968.CrossRefGoogle ScholarPubMed
25.Sharma, RK, Wang, JH.Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. J Biol Chem 1986; 261: 14160–14166.CrossRefGoogle ScholarPubMed
26.Sharma, RK, Adachi, AM, Adachi, K, et al. Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme by monoclonal antibodies. J Biol Chem 1984; 259: 9248–9254.CrossRefGoogle ScholarPubMed
27.Purvis, K, Olsen, A, Hansson, V.Calmodulin-dependent cyclic nucleotide phosphodiesterase in the immature rat testis. J Biol Chem 1981; 256: 11434–11441.CrossRefGoogle ScholarPubMed
28.Vandermeers, A, Vandermeers-Piret, MC, Rathe, J, et al. Purification and kinetic properties of two soluble forms of calmodulin-dependent cyclic nucleotide phosphodiesterase from rat pancreas. Biochem J 1983; 211: 341–347.CrossRefGoogle ScholarPubMed
29.Rossi, P, Giorgi, M, Geremia, R, et al. Testis specific calmodulindependent phosphodiesterase. A distinct high affinity cAMP isozyme immunologically related to brain calmodulin-dependent cGMP phosphodiesterase. J Biol Chem 1983; 263: 15521–15527.CrossRefGoogle Scholar
30.Sharma, RK, Kalra, J.Characterization of calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes. Biochem J 1994; 299: 97–100.CrossRefGoogle Scholar
31.Sharma, RK, Wang, JH.Differential regulation of calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme by cyclic-AMP dependent protein kinase and calmodulin dependent phosphatase. Proc Natl Acad Sci USA 1985; 82: 2603–2607.CrossRefGoogle ScholarPubMed
32.Florio, VA, Sonnenburg, WK, Johnson, R, et al. Phosphorylation of the 61 kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase at serine 120 reduces its affinity for calmodulin. Biochemistry 1994; 33: 8948–8954.CrossRefGoogle ScholarPubMed
33.Sharma, RK, Wang, JH.Regulation of 63 kDa subunit containing isozyme of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase by a calmodulin-dependent protein kinase. J Biol Chem 1986; 261: 1322–1328.CrossRefGoogle Scholar
34.Hashimoto, Y, Schworer, CM, Colbran, RJ, et al. Autophosphorylation of Ca2+/calmodulin protein kinase II: effects on total and Ca2+-independent activities and kinetic parameters. J Biol Chem 1987; 262: 8051–8055.CrossRefGoogle ScholarPubMed
35.Zhang, GY, Wang, JH, Sharma, RK.Purification and characterization of bovine brain calmodulin-dependent protein kinase II. The significance of autophosphorylation in the regulation of 63 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Mol Cell Biochem 1993; 22: 159–169.CrossRefGoogle Scholar
36.Sharma, RK, Wang, JH.Isolation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes. Methods Enzymol 1988; 159: 582–594.CrossRefGoogle ScholarPubMed
37.Voller, A, Bartlett, A, Bidwell, DE.Enzyme immune assay with special reference to ELISA technique. J Clin Pathol 1978; 31: 507–520.CrossRefGoogle Scholar
38.Sharma, RK, Wang, JH.Preparation and assay of the Ca2+-dependent modulator protein. Adv Cyclic Nucleotide Res 1979; 10: 187–198.Google ScholarPubMed
39.Laemmli, UK.Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685.CrossRefGoogle ScholarPubMed
40.Bradford, MM.A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principles of protein-dye binding. Anal Biochem 1976; 72: 248–254.CrossRefGoogle ScholarPubMed
41.Sharma, RK.Purification and characterization of novel calmodulin-binding protein from cardiac muscle. J Biol Chem 1990; 265: 1152–1157.CrossRefGoogle ScholarPubMed
42.Russell, DS, Rubenstein, LS.Pathology of Tumors of the Nervous System. Williams and Wilkins, 5th ed, 1990: 219–246.Google Scholar
43.Harsh, GR, Wilson, CB.Neuroepithelial Tumors of the Adult Brain, Youmans Neurological Surgery. New YorkW.B. Saunders, 1989; 5: 3040–3136.Google Scholar
44.Brostrom, C, Wolf, D.Calcium-dependent cyclic nucleotide phosphodiesterase from glial tumor cells. Arch Biochem Biophys 1974; 65: 715–727.CrossRefGoogle Scholar
45.Stefanovich, V, Ambrus, J, Karakousis, C, et al. Cyclic nucleotide phosphodiesterases in normal and malignant human tissue. J Medicine 1981; 12: 243–250.Google Scholar
46.Whitfield, JF, Boynton, AL, MacManus, JP, et al. The regulation of cell proliferation by calcium and cyclic AMP. Mol Cell Biochem 1979; 27: 155–179.CrossRefGoogle ScholarPubMed
47.Schuller, H.The signal transduction model of carcinogenesis. Biochem Pharm 1991; 42: 1511–1523.CrossRefGoogle ScholarPubMed